Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

1.

A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.

Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, Bauman JE, Hausman D, Walker L, Nemunaitis J, Rudin CM, Halmos B, Bowles DW.

J Thorac Oncol. 2014 Jul;9(7):1031-5. doi: 10.1097/JTO.0000000000000183.

PMID:
24926548
2.

Pathologic and gene expression features of metastatic melanomas to the brain.

Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S.

Cancer. 2013 Aug 1;119(15):2737-46. doi: 10.1002/cncr.28029. Epub 2013 May 21.

3.

The DEAD/DEAH box helicase, DDX11, is essential for the survival of advanced melanomas.

Bhattacharya C, Wang X, Becker D.

Mol Cancer. 2012 Nov 1;11:82. doi: 10.1186/1476-4598-11-82.

4.

Importance of glycolysis and oxidative phosphorylation in advanced melanoma.

Ho J, de Moura MB, Lin Y, Vincent G, Thorne S, Duncan LM, Hui-Min L, Kirkwood JM, Becker D, Van Houten B, Moschos SJ.

Mol Cancer. 2012 Oct 9;11:76. doi: 10.1186/1476-4598-11-76.

5.

Melanoma cell invasiveness is promoted at least in part by the epidermal growth factor-like repeats of tenascin-C.

Grahovac J, Becker D, Wells A.

J Invest Dermatol. 2013 Jan;133(1):210-20. doi: 10.1038/jid.2012.263. Epub 2012 Sep 6.

6.

Mitochondrial respiration--an important therapeutic target in melanoma.

Barbi de Moura M, Vincent G, Fayewicz SL, Bateman NW, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C, Kirkwood JM, Becker D, Conrads TP, Van Houten B, Moschos SJ.

PLoS One. 2012;7(8):e40690. doi: 10.1371/journal.pone.0040690. Epub 2012 Aug 17.

7.

Functional analysis and molecular targeting of aurora kinases a and B in advanced melanoma.

Wang X, Moschos SJ, Becker D.

Genes Cancer. 2010 Sep;1(9):952-63. doi: 10.1177/1947601910388936.

8.

Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma.

Abdullah C, Wang X, Becker D.

Cell Cycle. 2011 Mar 15;10(6):977-88. Epub 2011 Mar 15.

9.

Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes.

Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ.

Diabetes. 2010 Dec;59(12):3216-22. doi: 10.2337/db10-0862. Epub 2010 Aug 25.

10.

Molecular therapy for melanoma: useful and not useful targets.

Abdullah C, Wang X, Becker D.

Cancer Biol Ther. 2010 Jul 15;10(2):113-8. Epub 2010 Jul 4. Review. No abstract available.

11.

Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues.

Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M, Dhir R, Becker D.

Hum Pathol. 2010 Sep;41(9):1286-98. doi: 10.1016/j.humpath.2010.02.007. Epub 2010 Jun 18.

PMID:
20561671
12.

Proteomic analysis of laser microdissected melanoma cells from skin organ cultures.

Hood BL, Grahovac J, Flint MS, Sun M, Charro N, Becker D, Wells A, Conrads TP.

J Proteome Res. 2010 Jul 2;9(7):3656-63. doi: 10.1021/pr100164x.

13.

Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation.

Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D.

Cancer Biol Ther. 2009 Oct;8(19):1815-25. Epub .

14.

SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas.

Moschos SJ, Smith AP, Mandic M, Athanassiou C, Watson-Hurst K, Jukic DM, Edington HD, Kirkwood JM, Becker D.

Oncogene. 2007 Jun 21;26(29):4216-25. Epub 2007 Feb 12.

PMID:
17297476
15.

Markers and tissue resources for melanoma: meeting report.

Becker D, Mihm MC, Hewitt SM, Sondak VK, Fountain JW, Thurin M.

Cancer Res. 2006 Nov 15;66(22):10652-7.

16.

The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion.

Watson-Hurst K, Becker D.

Cancer Biol Ther. 2006 Oct;5(10):1375-82. Epub 2006 Oct 26.

18.

Expression analysis of genes identified by molecular profiling of VGP melanomas and MGP melanoma-positive lymph nodes.

McDonald SL, Edington HD, Kirkwood JM, Becker D.

Cancer Biol Ther. 2004 Jan;3(1):110-20. Epub 2004 Jan 24.

19.

SAGE identification and fluorescence imaging analysis of genes and transcripts in melanomas and precursor lesions.

Smith AP, Weeraratna AT, Spears JR, Meltzer PS, Becker D.

Cancer Biol Ther. 2004 Jan;3(1):104-9. Epub 2004 Jan 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk